Myriad Genetics Receives FDA Approval for Ovarian Cancer Test Companion Diagnostic

Myriad Genetics announced that the FDA approved its MyChoice CDx Test as a companion diagnostic for GSK's Zejula in advanced ovarian cancer patients. The test uses next-generation sequencing to identify homologous recombination deficiency (HRD) status and stratify patients. The approval reinforces Myriad's leadership in ovarian cancer diagnostics and highlights the importance of comprehensive HRD testing. Zejula is indicated for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond to first-line platinum-based chemotherapy and have HRD-positive status.